Enhanced IRAK4 Degraders for MYD88-Mutant B-Cell Lymphoma Treatment

This invention relates to improved methods and compositions for treating MYD88-mutant B-cell lymphomas using IRAK4 degraders, enhancing antitumor responses, and predicting patient responsiveness.

The original patent disclosed IRAK4 degraders for treating MYD88-mutant B-cell lymphomas. However, the original invention had limitations in terms of patient selection, treatment efficacy, and biomarker detection. The present inventive concept addresses these limitations by introducing new methods and compositions that enhance the antitumor response, predict patient responsiveness, and provide more effective treatment options.

The new inventive concept comprises four key aspects: (1) a method for treating MYD88-mutant B-cell lymphoma in patients who have previously received at least two prior therapies, (2) a system for monitoring the efficacy of IRAK4 degraders, (3) a method of enhancing the antitumor response of IRAK4 degraders by co-administering immunomodulatory agents, and (4) a pharmaceutical composition that enhances the bioavailability of Compound A. These aspects are designed to improve treatment outcomes, patient selection, and biomarker detection, ultimately providing more effective and personalized treatment options for patients with MYD88-mutant B-cell lymphomas.

The new claims introduce novel and non-obvious features that distinguish the inventive concept from the original patent. Specifically, the new claims provide a more targeted approach to patient selection, introduce new biomarkers for monitoring efficacy, and enhance the antitumor response through co-administration of immunomodulatory agents. These features provide a significant improvement over the original patent and demonstrate a non-obvious inventive step.

Alternative embodiments of the inventive concept could include varying the dosage and administration schedule of Compound A, using different immunomodulatory agents, or incorporating additional biomarkers for monitoring efficacy. These variations could provide further improvements in treatment outcomes and patient selection.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the development of targeted therapies for B-cell lymphomas. The market for IRAK4 degraders is expected to grow as the need for more effective and personalized treatment options increases. The inventive concept's ability to enhance antitumor responses, predict patient responsiveness, and provide more effective treatment options positions it for significant market share and commercial success.